Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
Identifieur interne : 003812 ( PubMed/Curation ); précédent : 003811; suivant : 003813Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
Auteurs : V. Bachanova [États-Unis] ; D I Marks [Royaume-Uni] ; M-J Zhang [États-Unis] ; H. Wang [États-Unis] ; M. De Lima [États-Unis] ; M D Aljurf [Arabie saoudite] ; M. Arellano [États-Unis] ; A S Artz [États-Unis] ; U. Bacher [Allemagne] ; J-Y Cahn [France] ; Y-B Chen [États-Unis] ; E A Copelan [États-Unis] ; W R Drobyski [États-Unis] ; R P Gale [Royaume-Uni] ; J P Greer [États-Unis] ; V. Gupta [Canada] ; G A Hale [États-Unis] ; P. Kebriaei [États-Unis] ; H M Lazarus [États-Unis] ; I D Lewis [Australie] ; V A Lewis [Canada] ; J L Liesveld [États-Unis] ; M R Litzow [États-Unis] ; A W Loren [États-Unis] ; A M Miller [États-Unis] ; M. Norkin [États-Unis] ; B. Oran [États-Unis] ; J. Pidala [États-Unis] ; J M Rowe [Israël] ; B N Savani [États-Unis] ; W. Saber [États-Unis] ; R. Vij [États-Unis] ; E K Waller [États-Unis] ; P H Wiernik [États-Unis] ; D J Weisdorf [États-Unis]Source :
- Leukemia [ 1476-5551 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Animaux, Chromosome Philadelphie, Cochons d'Inde, Conditionnement pour greffe, Femelle, Humains, Induction de rémission, Jeune adulte, Leucémie-lymphome lymphoblastique à précurseurs B et T (), Leucémie-lymphome lymphoblastique à précurseurs B et T (anatomopathologie), Maladie résiduelle, Mâle, Protein-tyrosine kinases (antagonistes et inhibiteurs), Taux de survie, Transplantation de moelle osseuse, Transplantation homologue.
- MESH :
- anatomopathologie : Leucémie-lymphome lymphoblastique à précurseurs B et T.
- antagonistes et inhibiteurs : Protein-tyrosine kinases.
- Adulte, Adulte d'âge moyen, Animaux, Chromosome Philadelphie, Cochons d'Inde, Conditionnement pour greffe, Femelle, Humains, Induction de rémission, Jeune adulte, Leucémie-lymphome lymphoblastique à précurseurs B et T, Maladie résiduelle, Mâle, Taux de survie, Transplantation de moelle osseuse, Transplantation homologue.
English descriptors
- KwdEn :
- Adult, Animals, Bone Marrow Transplantation, Female, Guinea Pigs, Humans, Male, Middle Aged, Neoplasm, Residual, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma (pathology), Precursor Cell Lymphoblastic Leukemia-Lymphoma (surgery), Protein-Tyrosine Kinases (antagonists & inhibitors), Remission Induction, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Young Adult.
- MESH :
- chemical , antagonists & inhibitors : Protein-Tyrosine Kinases.
- pathology : Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- surgery : Precursor Cell Lymphoblastic Leukemia-Lymphoma.
- Adult, Animals, Bone Marrow Transplantation, Female, Guinea Pigs, Humans, Male, Middle Aged, Neoplasm, Residual, Philadelphia Chromosome, Remission Induction, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Young Adult.
Abstract
The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD)(neg) pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P=0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P=0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P=0.62). Patients MRD(pos) pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P=0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P=0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P=0.057), but absence of pre-HCT TKI (HR 1.88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRD(pos) (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRD(neg) status is preferred pre-HCT.
DOI: 10.1038/leu.2013.253
PubMed: 23989431
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003927
Links to Exploration step
pubmed:23989431Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.</title><author><name sortKey="Bachanova, V" sort="Bachanova, V" uniqKey="Bachanova V" first="V" last="Bachanova">V. Bachanova</name><affiliation wicri:level="1"><nlm:affiliation>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN</wicri:regionArea></affiliation></author><author><name sortKey="Marks, D I" sort="Marks, D I" uniqKey="Marks D" first="D I" last="Marks">D I Marks</name><affiliation wicri:level="1"><nlm:affiliation>Bristol Adult BMT Unit, Bristol Children's Hospital, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Bristol Adult BMT Unit, Bristol Children's Hospital, Bristol</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, M J" sort="Zhang, M J" uniqKey="Zhang M" first="M-J" last="Zhang">M-J Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="Wang, H" sort="Wang, H" uniqKey="Wang H" first="H" last="Wang">H. Wang</name><affiliation wicri:level="1"><nlm:affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="De Lima, M" sort="De Lima, M" uniqKey="De Lima M" first="M" last="De Lima">M. De Lima</name><affiliation wicri:level="1"><nlm:affiliation>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH</wicri:regionArea></affiliation></author><author><name sortKey="Aljurf, M D" sort="Aljurf, M D" uniqKey="Aljurf M" first="M D" last="Aljurf">M D Aljurf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Arellano, M" sort="Arellano, M" uniqKey="Arellano M" first="M" last="Arellano">M. Arellano</name><affiliation wicri:level="1"><nlm:affiliation>Winship Cancer Institute, Emory University, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Winship Cancer Institute, Emory University, Atlanta, GA</wicri:regionArea></affiliation></author><author><name sortKey="Artz, A S" sort="Artz, A S" uniqKey="Artz A" first="A S" last="Artz">A S Artz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, University of Chicago Medicine, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, University of Chicago Medicine, Chicago, IL</wicri:regionArea></affiliation></author><author><name sortKey="Bacher, U" sort="Bacher, U" uniqKey="Bacher U" first="U" last="Bacher">U. Bacher</name><affiliation wicri:level="1"><nlm:affiliation>Klinik und Poliklinik fur Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik und Poliklinik fur Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Cahn, J Y" sort="Cahn, J Y" uniqKey="Cahn J" first="J-Y" last="Cahn">J-Y Cahn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, University Hospital, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, University Hospital, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Y B" sort="Chen, Y B" uniqKey="Chen Y" first="Y-B" last="Chen">Y-B Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Copelan, E A" sort="Copelan, E A" uniqKey="Copelan E" first="E A" last="Copelan">E A Copelan</name><affiliation wicri:level="1"><nlm:affiliation>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC</wicri:regionArea></affiliation></author><author><name sortKey="Drobyski, W R" sort="Drobyski, W R" uniqKey="Drobyski W" first="W R" last="Drobyski">W R Drobyski</name><affiliation wicri:level="1"><nlm:affiliation>Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="Gale, R P" sort="Gale, R P" uniqKey="Gale R" first="R P" last="Gale">R P Gale</name><affiliation wicri:level="1"><nlm:affiliation>Imperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Imperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London</wicri:regionArea></affiliation></author><author><name sortKey="Greer, J P" sort="Greer, J P" uniqKey="Greer J" first="J P" last="Greer">J P Greer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN</wicri:regionArea></affiliation></author><author><name sortKey="Gupta, V" sort="Gupta, V" uniqKey="Gupta V" first="V" last="Gupta">V. Gupta</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Hospital, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Hale, G A" sort="Hale, G A" uniqKey="Hale G" first="G A" last="Hale">G A Hale</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatric Hematology and Oncology, All Children's Hospital, St Petersburg, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatric Hematology and Oncology, All Children's Hospital, St Petersburg, FL</wicri:regionArea></affiliation></author><author><name sortKey="Kebriaei, P" sort="Kebriaei, P" uniqKey="Kebriaei P" first="P" last="Kebriaei">P. Kebriaei</name><affiliation wicri:level="1"><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Lazarus, H M" sort="Lazarus, H M" uniqKey="Lazarus H" first="H M" last="Lazarus">H M Lazarus</name><affiliation wicri:level="1"><nlm:affiliation>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH</wicri:regionArea></affiliation></author><author><name sortKey="Lewis, I D" sort="Lewis, I D" uniqKey="Lewis I" first="I D" last="Lewis">I D Lewis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia</wicri:regionArea></affiliation></author><author><name sortKey="Lewis, V A" sort="Lewis, V A" uniqKey="Lewis V" first="V A" last="Lewis">V A Lewis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Hematology and Oncology, Alberta Children's Hospital, Calgary, Alberta</wicri:regionArea></affiliation></author><author><name sortKey="Liesveld, J L" sort="Liesveld, J L" uniqKey="Liesveld J" first="J L" last="Liesveld">J L Liesveld</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY</wicri:regionArea></affiliation></author><author><name sortKey="Litzow, M R" sort="Litzow, M R" uniqKey="Litzow M" first="M R" last="Litzow">M R Litzow</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Internal Medicine, Mayo Clinic Rochester, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Loren, A W" sort="Loren, A W" uniqKey="Loren A" first="A W" last="Loren">A W Loren</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA</wicri:regionArea></affiliation></author><author><name sortKey="Miller, A M" sort="Miller, A M" uniqKey="Miller A" first="A M" last="Miller">A M Miller</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Baylor University Medical Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Baylor University Medical Center, Dallas, TX</wicri:regionArea></affiliation></author><author><name sortKey="Norkin, M" sort="Norkin, M" uniqKey="Norkin M" first="M" last="Norkin">M. Norkin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Shands HealthCare and University of Florida, Gainesville, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, Shands HealthCare and University of Florida, Gainesville, FL</wicri:regionArea></affiliation></author><author><name sortKey="Oran, B" sort="Oran, B" uniqKey="Oran B" first="B" last="Oran">B. Oran</name><affiliation wicri:level="1"><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Pidala, J" sort="Pidala, J" uniqKey="Pidala J" first="J" last="Pidala">J. Pidala</name><affiliation wicri:level="1"><nlm:affiliation>Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL</wicri:regionArea></affiliation></author><author><name sortKey="Rowe, J M" sort="Rowe, J M" uniqKey="Rowe J" first="J M" last="Rowe">J M Rowe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Rambam Medical Center, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Hematology, Rambam Medical Center, Haifa</wicri:regionArea></affiliation></author><author><name sortKey="Savani, B N" sort="Savani, B N" uniqKey="Savani B" first="B N" last="Savani">B N Savani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN</wicri:regionArea></affiliation></author><author><name sortKey="Saber, W" sort="Saber, W" uniqKey="Saber W" first="W" last="Saber">W. Saber</name><affiliation wicri:level="1"><nlm:affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="Vij, R" sort="Vij, R" uniqKey="Vij R" first="R" last="Vij">R. Vij</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bone Marrow Transplantation and Leukemia, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Bone Marrow Transplantation and Leukemia, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO</wicri:regionArea></affiliation></author><author><name sortKey="Waller, E K" sort="Waller, E K" uniqKey="Waller E" first="E K" last="Waller">E K Waller</name><affiliation wicri:level="1"><nlm:affiliation>Bone Marrow and Stem Cell Transplant Center, Emory University Hospital, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bone Marrow and Stem Cell Transplant Center, Emory University Hospital, Atlanta, GA</wicri:regionArea></affiliation></author><author><name sortKey="Wiernik, P H" sort="Wiernik, P H" uniqKey="Wiernik P" first="P H" last="Wiernik">P H Wiernik</name><affiliation wicri:level="1"><nlm:affiliation>Our Lady of Mercy Medical Center, Bronx, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Our Lady of Mercy Medical Center, Bronx, NY</wicri:regionArea></affiliation></author><author><name sortKey="Weisdorf, D J" sort="Weisdorf, D J" uniqKey="Weisdorf D" first="D J" last="Weisdorf">D J Weisdorf</name><affiliation wicri:level="1"><nlm:affiliation>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:23989431</idno><idno type="pmid">23989431</idno><idno type="doi">10.1038/leu.2013.253</idno><idno type="wicri:Area/PubMed/Corpus">003927</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003927</idno><idno type="wicri:Area/PubMed/Curation">003812</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003812</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.</title><author><name sortKey="Bachanova, V" sort="Bachanova, V" uniqKey="Bachanova V" first="V" last="Bachanova">V. Bachanova</name><affiliation wicri:level="1"><nlm:affiliation>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN</wicri:regionArea></affiliation></author><author><name sortKey="Marks, D I" sort="Marks, D I" uniqKey="Marks D" first="D I" last="Marks">D I Marks</name><affiliation wicri:level="1"><nlm:affiliation>Bristol Adult BMT Unit, Bristol Children's Hospital, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Bristol Adult BMT Unit, Bristol Children's Hospital, Bristol</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, M J" sort="Zhang, M J" uniqKey="Zhang M" first="M-J" last="Zhang">M-J Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="Wang, H" sort="Wang, H" uniqKey="Wang H" first="H" last="Wang">H. Wang</name><affiliation wicri:level="1"><nlm:affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="De Lima, M" sort="De Lima, M" uniqKey="De Lima M" first="M" last="De Lima">M. De Lima</name><affiliation wicri:level="1"><nlm:affiliation>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH</wicri:regionArea></affiliation></author><author><name sortKey="Aljurf, M D" sort="Aljurf, M D" uniqKey="Aljurf M" first="M D" last="Aljurf">M D Aljurf</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Arellano, M" sort="Arellano, M" uniqKey="Arellano M" first="M" last="Arellano">M. Arellano</name><affiliation wicri:level="1"><nlm:affiliation>Winship Cancer Institute, Emory University, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Winship Cancer Institute, Emory University, Atlanta, GA</wicri:regionArea></affiliation></author><author><name sortKey="Artz, A S" sort="Artz, A S" uniqKey="Artz A" first="A S" last="Artz">A S Artz</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, University of Chicago Medicine, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, University of Chicago Medicine, Chicago, IL</wicri:regionArea></affiliation></author><author><name sortKey="Bacher, U" sort="Bacher, U" uniqKey="Bacher U" first="U" last="Bacher">U. Bacher</name><affiliation wicri:level="1"><nlm:affiliation>Klinik und Poliklinik fur Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik und Poliklinik fur Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Cahn, J Y" sort="Cahn, J Y" uniqKey="Cahn J" first="J-Y" last="Cahn">J-Y Cahn</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, University Hospital, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, University Hospital, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Y B" sort="Chen, Y B" uniqKey="Chen Y" first="Y-B" last="Chen">Y-B Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Copelan, E A" sort="Copelan, E A" uniqKey="Copelan E" first="E A" last="Copelan">E A Copelan</name><affiliation wicri:level="1"><nlm:affiliation>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC</wicri:regionArea></affiliation></author><author><name sortKey="Drobyski, W R" sort="Drobyski, W R" uniqKey="Drobyski W" first="W R" last="Drobyski">W R Drobyski</name><affiliation wicri:level="1"><nlm:affiliation>Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="Gale, R P" sort="Gale, R P" uniqKey="Gale R" first="R P" last="Gale">R P Gale</name><affiliation wicri:level="1"><nlm:affiliation>Imperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Imperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London</wicri:regionArea></affiliation></author><author><name sortKey="Greer, J P" sort="Greer, J P" uniqKey="Greer J" first="J P" last="Greer">J P Greer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN</wicri:regionArea></affiliation></author><author><name sortKey="Gupta, V" sort="Gupta, V" uniqKey="Gupta V" first="V" last="Gupta">V. Gupta</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Hospital, Toronto, Ontario</wicri:regionArea></affiliation></author><author><name sortKey="Hale, G A" sort="Hale, G A" uniqKey="Hale G" first="G A" last="Hale">G A Hale</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatric Hematology and Oncology, All Children's Hospital, St Petersburg, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatric Hematology and Oncology, All Children's Hospital, St Petersburg, FL</wicri:regionArea></affiliation></author><author><name sortKey="Kebriaei, P" sort="Kebriaei, P" uniqKey="Kebriaei P" first="P" last="Kebriaei">P. Kebriaei</name><affiliation wicri:level="1"><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Lazarus, H M" sort="Lazarus, H M" uniqKey="Lazarus H" first="H M" last="Lazarus">H M Lazarus</name><affiliation wicri:level="1"><nlm:affiliation>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH</wicri:regionArea></affiliation></author><author><name sortKey="Lewis, I D" sort="Lewis, I D" uniqKey="Lewis I" first="I D" last="Lewis">I D Lewis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia</wicri:regionArea></affiliation></author><author><name sortKey="Lewis, V A" sort="Lewis, V A" uniqKey="Lewis V" first="V A" last="Lewis">V A Lewis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Hematology and Oncology, Alberta Children's Hospital, Calgary, Alberta</wicri:regionArea></affiliation></author><author><name sortKey="Liesveld, J L" sort="Liesveld, J L" uniqKey="Liesveld J" first="J L" last="Liesveld">J L Liesveld</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY</wicri:regionArea></affiliation></author><author><name sortKey="Litzow, M R" sort="Litzow, M R" uniqKey="Litzow M" first="M R" last="Litzow">M R Litzow</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Internal Medicine, Mayo Clinic Rochester, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Loren, A W" sort="Loren, A W" uniqKey="Loren A" first="A W" last="Loren">A W Loren</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA</wicri:regionArea></affiliation></author><author><name sortKey="Miller, A M" sort="Miller, A M" uniqKey="Miller A" first="A M" last="Miller">A M Miller</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Baylor University Medical Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Baylor University Medical Center, Dallas, TX</wicri:regionArea></affiliation></author><author><name sortKey="Norkin, M" sort="Norkin, M" uniqKey="Norkin M" first="M" last="Norkin">M. Norkin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Oncology, Shands HealthCare and University of Florida, Gainesville, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Oncology, Shands HealthCare and University of Florida, Gainesville, FL</wicri:regionArea></affiliation></author><author><name sortKey="Oran, B" sort="Oran, B" uniqKey="Oran B" first="B" last="Oran">B. Oran</name><affiliation wicri:level="1"><nlm:affiliation>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Pidala, J" sort="Pidala, J" uniqKey="Pidala J" first="J" last="Pidala">J. Pidala</name><affiliation wicri:level="1"><nlm:affiliation>Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL</wicri:regionArea></affiliation></author><author><name sortKey="Rowe, J M" sort="Rowe, J M" uniqKey="Rowe J" first="J M" last="Rowe">J M Rowe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Rambam Medical Center, Haifa, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Hematology, Rambam Medical Center, Haifa</wicri:regionArea></affiliation></author><author><name sortKey="Savani, B N" sort="Savani, B N" uniqKey="Savani B" first="B N" last="Savani">B N Savani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN</wicri:regionArea></affiliation></author><author><name sortKey="Saber, W" sort="Saber, W" uniqKey="Saber W" first="W" last="Saber">W. Saber</name><affiliation wicri:level="1"><nlm:affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea></affiliation></author><author><name sortKey="Vij, R" sort="Vij, R" uniqKey="Vij R" first="R" last="Vij">R. Vij</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bone Marrow Transplantation and Leukemia, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Bone Marrow Transplantation and Leukemia, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO</wicri:regionArea></affiliation></author><author><name sortKey="Waller, E K" sort="Waller, E K" uniqKey="Waller E" first="E K" last="Waller">E K Waller</name><affiliation wicri:level="1"><nlm:affiliation>Bone Marrow and Stem Cell Transplant Center, Emory University Hospital, Atlanta, GA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bone Marrow and Stem Cell Transplant Center, Emory University Hospital, Atlanta, GA</wicri:regionArea></affiliation></author><author><name sortKey="Wiernik, P H" sort="Wiernik, P H" uniqKey="Wiernik P" first="P H" last="Wiernik">P H Wiernik</name><affiliation wicri:level="1"><nlm:affiliation>Our Lady of Mercy Medical Center, Bronx, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Our Lady of Mercy Medical Center, Bronx, NY</wicri:regionArea></affiliation></author><author><name sortKey="Weisdorf, D J" sort="Weisdorf, D J" uniqKey="Weisdorf D" first="D J" last="Weisdorf">D J Weisdorf</name><affiliation wicri:level="1"><nlm:affiliation>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN</wicri:regionArea></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="eISSN">1476-5551</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Bone Marrow Transplantation</term><term>Female</term><term>Guinea Pigs</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm, Residual</term><term>Philadelphia Chromosome</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (pathology)</term><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma (surgery)</term><term>Protein-Tyrosine Kinases (antagonists & inhibitors)</term><term>Remission Induction</term><term>Survival Rate</term><term>Transplantation Conditioning</term><term>Transplantation, Homologous</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Chromosome Philadelphie</term><term>Cochons d'Inde</term><term>Conditionnement pour greffe</term><term>Femelle</term><term>Humains</term><term>Induction de rémission</term><term>Jeune adulte</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T ()</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T (anatomopathologie)</term><term>Maladie résiduelle</term><term>Mâle</term><term>Protein-tyrosine kinases (antagonistes et inhibiteurs)</term><term>Taux de survie</term><term>Transplantation de moelle osseuse</term><term>Transplantation homologue</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Protein-Tyrosine Kinases</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protein-tyrosine kinases</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Bone Marrow Transplantation</term><term>Female</term><term>Guinea Pigs</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm, Residual</term><term>Philadelphia Chromosome</term><term>Remission Induction</term><term>Survival Rate</term><term>Transplantation Conditioning</term><term>Transplantation, Homologous</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Chromosome Philadelphie</term><term>Cochons d'Inde</term><term>Conditionnement pour greffe</term><term>Femelle</term><term>Humains</term><term>Induction de rémission</term><term>Jeune adulte</term><term>Leucémie-lymphome lymphoblastique à précurseurs B et T</term><term>Maladie résiduelle</term><term>Mâle</term><term>Taux de survie</term><term>Transplantation de moelle osseuse</term><term>Transplantation homologue</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD)(neg) pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P=0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P=0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P=0.62). Patients MRD(pos) pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P=0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P=0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P=0.057), but absence of pre-HCT TKI (HR 1.88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRD(pos) (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRD(neg) status is preferred pre-HCT.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23989431</PMID><DateCreated><Year>2014</Year><Month>03</Month><Day>05</Day></DateCreated><DateCompleted><Year>2014</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.</ArticleTitle><Pagination><MedlinePgn>658-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2013.253</ELocationID><Abstract><AbstractText>The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD)(neg) pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P=0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P=0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P=0.62). Patients MRD(pos) pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P=0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P=0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P=0.057), but absence of pre-HCT TKI (HR 1.88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRD(pos) (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRD(neg) status is preferred pre-HCT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bachanova</LastName><ForeName>V</ForeName><Initials>V</Initials><Identifier Source="ORCID">000000029325432X</Identifier><AffiliationInfo><Affiliation>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>D I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Bristol Adult BMT Unit, Bristol Children's Hospital, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>M-J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lima</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aljurf</LastName><ForeName>M D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arellano</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Winship Cancer Institute, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artz</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, University of Chicago Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacher</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Klinik und Poliklinik fur Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahn</LastName><ForeName>J-Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Hematology, University Hospital, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Y-B</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Department of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Copelan</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drobyski</LastName><ForeName>W R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gale</LastName><ForeName>R P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Imperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greer</LastName><ForeName>J P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Princess Margaret Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hale</LastName><ForeName>G A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology and Oncology, All Children's Hospital, St Petersburg, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kebriaei</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarus</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>I D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>V A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesveld</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litzow</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Hematology and Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loren</LastName><ForeName>A W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Oncology, Baylor University Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norkin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Oncology, Shands HealthCare and University of Florida, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oran</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pidala</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Rambam Medical Center, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savani</LastName><ForeName>B N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saber</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vij</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Bone Marrow Transplantation and Leukemia, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waller</LastName><ForeName>E K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Bone Marrow and Stem Cell Transplant Center, Emory University Hospital, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiernik</LastName><ForeName>P H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Our Lady of Mercy Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisdorf</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U10 HL069294</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA016672</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA076518</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000114</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR000113</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Blood. 2010 Nov 25;116(22):4439-43</RefSource><PMID Version="1">20716774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2013 Jul;48(7):982-7</RefSource><PMID Version="1">23318533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2002 Oct 1;100(7):2357-66</RefSource><PMID Version="1">12239143</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2003 Jan;120(1):145-53</RefSource><PMID Version="1">12492591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Jun 15;103(12):4396-407</RefSource><PMID Version="1">14551133</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 1994 Oct;8(10):1688-95</RefSource><PMID Version="1">7934164</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 1999 Mar 30;18(6):695-706</RefSource><PMID Version="1">10204198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Nov 15;104(10):3028-37</RefSource><PMID Version="1">15256423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2005 Apr;19(4):628-35</RefSource><PMID Version="1">15744351</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Jul 15;106(2):458-63</RefSource><PMID Version="1">15817679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Oct 15;106(8):2912-9</RefSource><PMID Version="1">15994282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Jun 15;106(12):2657-63</RefSource><PMID Version="1">16703597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2006 Sep;20(9):1526-32</RefSource><PMID Version="1">16838024</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Feb 15;109(4):1408-13</RefSource><PMID Version="1">17062730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Apr 15;109(8):3189-97</RefSource><PMID Version="1">17170120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 May 1;109(9):3676-8</RefSource><PMID Version="1">17213285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 May 15;109(10):2068-76</RefSource><PMID Version="1">17429836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Jul 15;110(2):727-34</RefSource><PMID Version="1">17405907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Feb 15;111(4):1827-33</RefSource><PMID Version="1">18048644</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58</RefSource><PMID Version="1">18541193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Aug 1;112(3):903-9</RefSource><PMID Version="1">18519812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2008 Nov;143(4):503-10</RefSource><PMID Version="1">18986386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9</RefSource><PMID Version="1">19203728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Mar 26;113(13):2902-5</RefSource><PMID Version="1">19179301</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Apr 30;113(18):4153-62</RefSource><PMID Version="1">19141862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 May 7;113(19):4489-96</RefSource><PMID Version="1">19244158</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2009 Nov;15(11):1407-14</RefSource><PMID Version="1">19822300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2009 Oct;23(10):1763-70</RefSource><PMID Version="1">19440217</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2010 Jan;95(1):87-95</RefSource><PMID Version="1">19797728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2010 Feb 25;115(8):1512-8</RefSource><PMID Version="1">20007806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2010 Jul 22;116(3):366-74</RefSource><PMID Version="1">20404137</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Aug 1;28(22):3644-52</RefSource><PMID Version="1">20606084</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jun 20;29(18):2493-8</RefSource><PMID Version="1">21576633</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jun 23;117(25):6963-70</RefSource><PMID Version="1">21464372</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2011 Aug;96(8):1113-20</RefSource><PMID Version="1">21508120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Dec 15;118(25):6521-8</RefSource><PMID Version="1">21931113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 2012 May;32(5):1779-83</RefSource><PMID Version="1">22593461</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2013 Jan;19(1):150-5</RefSource><PMID Version="1">22960387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Apr 18;368(16):1509-18</RefSource><PMID Version="1">23527958</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Jun;27(6):1411-3</RefSource><PMID Version="1">23138184</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Jun;27(6):1254-62</RefSource><PMID Version="1">23212150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2011 Jan;25(1):41-7</RefSource><PMID Version="1">20944676</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="Y">Bone Marrow Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="Y">Neoplasm, Residual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010677" MajorTopicYN="Y">Philadelphia Chromosome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054198" MajorTopicYN="N">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="Y">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="Y">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019172" MajorTopicYN="Y">Transplantation Conditioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS549962</OtherID><OtherID Source="NLM">PMC3951192</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23989431</ArticleId><ArticleId IdType="pii">leu2013253</ArticleId><ArticleId IdType="doi">10.1038/leu.2013.253</ArticleId><ArticleId IdType="pmc">PMC3951192</ArticleId><ArticleId IdType="mid">NIHMS549962</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003812 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003812 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23989431
|texte= Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23989431" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |